HC Wainwright & Co. Reiterates Buy on Cartesian Therapeutics, Maintains $54 Price Target

Benzinga · 05/09 19:24
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $54 price target.